Results 311 to 320 of about 1,218,074 (349)
Some of the next articles are maybe not open access.

Malnutrition and chronic heart failure

Mediterranean Journal of Nutrition and Metabolism, 2008
Malnutrition in patients with chronic heart failure (CHF) is not always as severe as muscle wasting in the same patients. Our data showed that 24% of patients with CHF had malnutrition (serum albumin < 3.5 g/dl) while 68% had muscle atrophy. This apparent discrepancy can be explained by considering the metabolic role of the striate muscle.
E. Pasini, R. Aquilani, F.S. Dioguardi
openaire   +2 more sources

Bisoprolol in chronic heart failure

Hospital Medicine, 2000
The evidence for the use of beta-blockers in heart failure is substantial. Latest recommendations and guidelines suggest that most heart failure patients should be on a drug regimen of an angiotensin-converting enzyme inhibitor, diuretic and a beta-blocker.
openaire   +2 more sources

The Management of Chronic Heart Failure

New England Journal of Medicine, 1996
Heart failure is a complex of symptoms — fatigue, shortness of breath, and congestion — that are related to the inadequate perfusion of tissue during exertion and often to the retention of fluid. Its primary cause is an impairment of the heart's ability to fill or empty the left ventricle properly.
openaire   +2 more sources

Inflammation in Chronic Heart Failure

Annals of Pharmacotherapy, 2008
Objective: To summarize findings regarding the association of inflammatory processes with chronic heart failure (HF). Data Sources: We conducted PubMed/MEDLINE searches (1966–January 2006) of primary literature using the following key words: ACE inhibitors, allopurinol, angiotensin-receptor antagonists, cardiomyopathy, chemokines, cytokines, diuretics,
Roy C. Parish, Jeffery D Evans
openaire   +2 more sources

Management of chronic heart failure

Drugs of Today, 1999
Although chronic heart failure remains a major source of morbidity and mortality, recent advances in treatment have resulted in substantial improvements in survival, quality of life and exercise capacity, while at the same time reducing hospitalizations and overall cost of care.
openaire   +3 more sources

Valsartan in Chronic Heart Failure

Annals of Pharmacotherapy, 2005
OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases were searched (1983–June 2004) using the key words angiotensin-receptor blocker, heart failure, valsartan, Diovan, and angiotensin-converting enzyme inhibitor.
openaire   +3 more sources

The pathophysiology of chronic heart failure

Perfusion, 2000
Although the reduction in cardiac function is the cause and central abnormality of heart failure, there is clearly a very wide range of abnormalities in other systems that contribute to both the symptoms and progression of the syndrome of CHF. We must be aware of these changes to use the available therapeutic options to maximal effect, as well as being
openaire   +3 more sources

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)

The Lancet, 1999
A. Hjalmarson   +350 more
semanticscholar   +1 more source

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

The Lancet, 2003
S. Yusuf   +8 more
semanticscholar   +1 more source

Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers

Heart Failure Reviews, 2020
F. Triposkiadis   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy